Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

A personalized cancer vaccine from Moderna and Merck showed promise during a late-stage melanoma trial. The study found that the combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.